American Society of Hematology (ASH)

The American Society of Hematology (ASH) is a professional organization representing hematologists. It was founded in 1958. Its annual meeting is held in December of every year and has attracted more than 30,000 attendees. The society publishes the medical journal Blood, the most cited peer-reviewed publication in the field, which is available weekly in print and online, as well as the newly launched, online, peer-reviewed open-access journal, Blood Advances.

A pharmacokinetic and safety study of ixazomib in patients with severe renal impairment or end-stage renal disease requiring hemodialysis demonstrated that this patient subgroup requires dose modification of ixazomib due to a 38% higher, unbound systemic exposure. Administration of ixazomib may be administered without regard to the timing of dialysis. Read More ›

Dose-Finding Phase 2 Trial of Single-Agent Isatuximab in Relapsed/Refractory Multiple Myeloma

ASH 2015 – Multiple Myeloma

Researchers presented data relating to the management of infusion-related reactions (IRRs) associated with single-agent daratumumab treatment in patients with relapsed or refractory multiple myeloma (RRMM) enrolled in the open-label, multicenter, phase 2 Sirius study. Read More ›

Ixazomib plus Panobinostat and Dexamethasone in Heavily Pretreated Patients with RRMM

ASH 2015 – Multiple Myeloma

Investigators propose moving to a phase 2 evaluation after using a new treatment regimen that was well-tolerated in patients with progressive disease consisting of panobinostat at 20 mg 3 times a week every other week to ixazomib at target 4 mg weekly, 3 weeks on, 1 week off, with dexamethasone 20 mg on the day of and after ixazomib. Read More ›

Blinatumomab Treatment in Adult Patients with Relapsed/Refractory B-Precursor ALL Post-Allogeneic Hematopoietic Stem-Cell Transplantation

ASH 2015 – Leukemia

ASH 2015 – Multiple Myeloma

Researchers reported results of an online survey that examined the preferences of patients with multiple myeloma (MM) on route of administration and individual treatment-related adverse events. Read More ›

Subgroup Analysis Based on Cytogenetic Risk Status: Carfilzomib / Lenalidomide / Dexamethasone versus Lenalidomide / Dexamethasone (ASPIRE Study)

ASH 2015 – Multiple Myeloma

American Society of Hematology (ASH)

Page 36 of 44